Signal Genetics is a biotechnology startup that aims to empower physicians with precise, actionable insights for superior cancer care decisions. The company, founded in 2010, specializes in molecular diagnostics and offers advanced diagnostic services to assist physicians in making well-informed decisions for cancer patient care. Signal Genetics became the exclusive licensee of renowned research on multiple myeloma from the University of Arkansas for Medical Sciences (UAMS), with over 30 years of clinical research involving nearly 10,000 multiple myeloma patients contributing to the development of its primary product, MyPRS® (Myeloma Prognostic Risk Signature).
The last known investment in Signal Genetics was a $25.00M Convertible Note investment at 01 January 2011 led by BSL Capital.
Signal Genetics operates in the Biotechnology and Health Care industries, positioning itself to make a significant impact in the field of cancer care through cutting-edge diagnostic solutions.
